Clicky

NeuBase Therapeutics Inc(O7PA)

Description: NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.


Keywords: Medicine Biotechnology Cancer Organ Systems Dystrophy Huntington's Disease Kras Genetic Disorder Rare Genetic Diseases Myotonic Dystrophy Oncology Applications Preclinical Stage Biopharmaceutical Antisense Therapy

Home Page: www.neubasetherapeutics.com

350 Technology Drive
Pittsburgh, PA 15219
United States
Phone: 646 450 1790


Officers

Name Title
Dr. Dietrich A. Stephan Ph.D. Founder, CEO & Director
Mr. Todd P. Branning CFO & Sec.
Dr. Curt Bradshaw Ph.D. Chief Scientific Officer
Mr. Alan Scrivner J.D. Gen. Counsel
Ms. Shannon McCarthy Chief People Officer
Dr. Robert J. Zamboni Ph.D. Chief of Preclinical Devel. & Member of Scientific Advisory Board
Dr. Ron Sarkar M.B.A., Ph.D. Sr. VP of Corp. Strategy & Bus. Devel.

Exchange: F

Country: DE

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.2022
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: September
Full Time Employees: 37
Back to stocks